CSL has announced the US Food
and Drug Administration approval
of its AFSTYLA (Antihaemophilic
Factor [Recombinant] Single
Chain), which is a novel long-lasting
recombinant factor VIII single-chain
therapy for adults and children
with haemophilia A made by its CSL
Behring offshoot.
AFSTYLA is indicated for routine
prophylaxis to prevent or reduce
the frequency of bleeding
episodes and for the perioperative
management of bleeding.
The company said AFSTYLA is
expected to become available in
the US in the coming weeks, with
chief scientific officer Andrew
Cuthbertson saying he was looking
forward to the positive impact
it can have on patients with
haemophilia A.The above article was sent to subscribers in Pharmacy Daily's issue from 27 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 27 May 16
THE role and significance of community pharmacy in regional areas was a key focus of discussion for the Nationals leader David Littleproud during last week’s visit to Orana Mall Pharmacy as part of a regional tour.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.